Infliximab-induced optic neuritis

Antitumour necrosis factor alpha agents are important treatments in many inflammatory conditions including rheumatoid arthritis, psoriatic arthritis and the inflammatory bowel diseases. However, there have been case reports of optic neuritis and other demyelinating diseases as complications of these...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ case reports 2020-12, Vol.13 (12), p.e236041
Hauptverfasser:	Dermawan, Andrew, So, Kenji, Venugopal, Kannan, Picardo, Sherman
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use biological agents Blindness - diagnosis Blindness - drug therapy Blindness - immunology Case Report Case reports Colitis, Ulcerative - drug therapy Colitis, Ulcerative - immunology Drug dosages Drug Substitution drugs: CNS (not psychiatric) Field study Gastrointestinal Agents - adverse effects Humans Immunotherapy Infections Inflammatory bowel disease Infliximab - adverse effects Laboratories Magnetic Resonance Imaging Male Middle Aged Monoclonal antibodies neuroopthalmology Optic nerve Optic Nerve - diagnostic imaging Optic Nerve - drug effects Optic Nerve - immunology Optic Neuritis - complications Optic Neuritis - diagnosis Optic Neuritis - drug therapy Optic Neuritis - immunology Optics Prednisolone - therapeutic use Rheumatoid arthritis TNF inhibitors Tomography, Optical Coherence Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - immunology Tumor necrosis factor-TNF Visual Acuity Visual Field Tests Visual Fields visual pathway
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Antitumour necrosis factor alpha agents are important treatments in many inflammatory conditions including rheumatoid arthritis, psoriatic arthritis and the inflammatory bowel diseases. However, there have been case reports of optic neuritis and other demyelinating diseases as complications of these agents. This case report presents a patient with ulcerative colitis on infliximab who presented with sudden onset mono-ocular visual field loss and highlights the diagnosis and management of infliximab-induced optic neuritis.
ISSN:	1757-790X 1757-790X
DOI:	10.1136/bcr-2020-236041